Key result
Diabetes in children, pregnant women, and their newborns was associated with high fast-antiplasmin levels and low or missing slow-antiplasmin levels compared to healthy controls.
Why the study?
Are levels of fibrinolytic inhibitors altered in diabetic children, pregnant women, and their offspring compared to healthy controls?
Observational
Are levels of fibrinolytic inhibitors altered in diabetic children, pregnant women, and their offspring compared to healthy controls?
Diabetic patients and their offspring exhibit altered levels of fibrinolytic inhibitors, which may contribute to their increased susceptibility to thrombosis.
Answers are grounded in this paper and cite their sources.
May suggest heightened thrombotic susceptibility via fibrinolytic imbalance in diabetic offspring; hypothesis-generating and requires prospective validation.
Late diabetic complications are often related to vascular changes and formation of thrombi in the altered vasculature. Contributing factors to thrombosis susceptibility of diabetic patients include changes in clotting factors, platelets, and inhibition of fibrinolysis. We have measured various fibrinolytic inhibitors in the blood of diabetic children, diabetic pregnant women and their offspring, and healthy controls. Inhibitors studied included 1) fast (immediate) antiplasmin, 2) slow (progressive) antiplasmin, 3) alpha-2-macroglobulin, and 4) alpha-1-antitrypsin. It appears from our study that high fast-antiplasmin levels, and low or missing slow-antiplasmin levels are characteristic of diabetic patients and of newborn of diabetic mothers. The reason for high fast-antiplasmin levels is not clear: Levels are not connected with the age of the patient or duration of diabetes, and are not elevated in response to a fibrinolytic process (fibrin decomposition products could not be shown to be present in the serum of diabetic children). Alpha-2-macroglobulin was significantly higher and alpha-1-antitrypsin significantly lower in diabetic women than in controls. In the other groups of patients studied differences in these inhibitors from the appropriate control groups were not statistically significant.
No takes yet. Share an insight, caveat, or question.
Ambrus et al. (1979) conducted an observational in Diabetes. Diabetes vs. Healthy controls was evaluated on Levels of fibrinolytic inhibitors (fast antiplasmin, slow antiplasmin, alpha-2-macroglobulin, alpha-1-antitrypsin). Diabetes in children, pregnant women, and their newborns was associated with high fast-antiplasmin levels and low or missing slow-antiplasmin levels compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: